Inflammatory atherosclerosis as an emerging immunology target
Anti-IL-6 and other inflammation-targeted programs are testing whether atherosclerosis is treatable as an immunology target.
The CANTOS trial established inflammatory atherosclerosis as a real target a decade ago. Late-stage programs targeting IL-6 and related inflammatory pathways in cardiovascular disease are now reading out. If outcomes confirm, this opens a major new commercial category at the intersection of immunology and cardiology with implications for both fields.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
PipelineTreatmentDrug development
← Back to Signals
Published by PatientSpotlight, by PanaceaIntel.